117 related articles for article (PubMed ID: 6393227)
1. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
Chwistecki K; Mrukowicz M; Kopel E
Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
[No Abstract] [Full Text] [Related]
2. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Sznajderman M
Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
[No Abstract] [Full Text] [Related]
3. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
Bartnikowska E; Michajlik A; Wegrzyn B
Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
[No Abstract] [Full Text] [Related]
4. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
[No Abstract] [Full Text] [Related]
5. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Bolzano K; Krempler F; Schellenberg B; Schlierf G
Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
[TBL] [Abstract][Full Text] [Related]
6. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
[No Abstract] [Full Text] [Related]
8. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
Goranov I; Naumova R; Kerekovska M; Balabanski L
Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
[TBL] [Abstract][Full Text] [Related]
9. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV].
Chwistecki K; Mrukowicz M; Kopel E
Wiad Lek; 1985 Apr; 38(7):490-4. PubMed ID: 4013323
[No Abstract] [Full Text] [Related]
10. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Noseda G; Fragiacomo C; Weidmann P; Bachmann C
Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
[TBL] [Abstract][Full Text] [Related]
11. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
Sznajderman M
Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
[No Abstract] [Full Text] [Related]
12. Clinical experience with bezafibrate.
Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
Artery; 1980; 8(6):553-9. PubMed ID: 7259534
[TBL] [Abstract][Full Text] [Related]
13. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Artery; 1980; 8(2):113-9. PubMed ID: 7458676
[TBL] [Abstract][Full Text] [Related]
14. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
Uglesić A; Ljachnicky N
Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534
[No Abstract] [Full Text] [Related]
15. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
[TBL] [Abstract][Full Text] [Related]
16. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
17. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
[No Abstract] [Full Text] [Related]
18. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
Bradford RH; Goldberg AC; Schonfeld G; Knopp RH
Atherosclerosis; 1992 Jan; 92(1):31-40. PubMed ID: 1575820
[TBL] [Abstract][Full Text] [Related]
19. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
[No Abstract] [Full Text] [Related]
20. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial.
Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A
Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
